Vanderbilt-Ingram Cancer Center | Strategic Alliance Partners

April 03, 2023

Expert panelists identify key takeaways and share their excitement for future directions in the management of metastatic colorectal cancer.

March 27, 2023

Before closing out their review of combination therapy in metastatic colorectal cancer, panelists discuss the STELLAR-303 and SUNLIGHT clinical trials.

March 27, 2023

A comprehensive review on combination strategies with immune checkpoint and tyrosine kinase inhibitors in patients with metastatic colorectal cancer.

March 22, 2023

Hematologists and oncologists are uniquely poised to aid in the identification of patients with hereditary hemorrhagic telangiectasia and assist in their care, and it is important for the practicing clinician to familiarize oneself with the symptoms of hereditary hemorrhagic telangiectasia to avoid overlooking the diagnosis.

March 20, 2023

A focused discussion on combination strategies with immune checkpoint inhibitors in patients with metastatic colorectal cancer.

March 20, 2023

Switching their focus to immune checkpoint inhibitors, panelists provide an overview on the role of immunotherapy in metastatic colorectal cancer.

March 16, 2023

Investigators are unclear about the factors driving the explosive growth in incidence of appendiceal cancer over the past 2 decades.

March 13, 2023

Before closing out their discussion on BRAF-mutated metastatic colorectal cancer, panelists consider other novel combination strategies in this setting.

March 13, 2023

Shared insight on the BREAKWATER trial, which combined encorafenib, cetuximab, and chemotherapy in patients with BRAF V600E–mutated metastatic colorectal cancer.

March 06, 2023

Expert perspectives on the BEACON CRC trial, which combined encorafenib, cetuximab, and binimetinib in patients with BRAF V600E–mutated metastatic colorectal cancer.

March 06, 2023

Following its discussion on trastuzumab deruxtecan and tucatinib therapy in HER2+ mCRC, the panel emphasizes the importance HER2 status identification in metastatic colorectal cancer.

February 27, 2023

Switching their focus to tucatinib, expert panelists review data from the MOUNTAINEER study and define the role of tucatinib in managing HER2+ metastatic colorectal cancer.

February 27, 2023

Comprehensive insight on the adverse event profile of antibody drug conjugate therapy as it compares to other agents in HER2+ metastatic colorectal cancer management.

February 23, 2023

Brian I. Rini, MD, discusses standard and investigational treatment options for patients with RCC who are refractory to immunotherapy; the potential role of biomarkers in future targeted treatments; and the need for novel mechanisms such as HIF inhibition to meet the needs of patients who don’t respond to immunotherapy or VEGF TKIs.

February 20, 2023

Centering discussion on clinical trials and experience with trastuzumab deruxtecan, expert oncologists identify its value in the HER2+ treatment landscape.

February 20, 2023

After a brief overview on first-line treatment options for patients with metastatic colorectal cancer, panelists highlight the role HER2 status plays in the selection of novel therapies.

February 16, 2023

A comprehensive discussion on the barriers to molecular testing in metastatic colorectal cancer, along with challenges in utilizing these tests in the real-world setting.

February 16, 2023

Panelists consider the potential role for circulating tumor DNA to inform the selection of therapy for patients with metastatic colorectal cancer.

February 14, 2023

Brian I. Rini, MD, FASCO, discusses the current treatment landscape for patients with relapsed/refractory renal cell carcinoma.

February 13, 2023

Tae Kon Kim, MD, PhD, discusses key results on the synergistic effects of PD-1H blockade in acute myeloid leukemia..